iSynergies™赛聚能™技术是哈佛大学联合美国Sinclair Group辛克莱生物实验室联合推出的革命性生物医药能效聚合技术，也称协同增效技术，主要用于尖端生物医药品领域医药效能提升，该技术打破了数十年来普通生物医药产品成分单一造成的潜能限制或成分叠加造成的成分竞争性拮抗，可以将不同核心成分深度融入彼此基团发挥药品最大效能。该技术还包含AMPK激活剂融合技术，目的是实现核心成分全效吸收。同时该技术还解决了同等产品对不同人群的免疫抵抗，解决了“药同效不同”的历史难题。该技术被誉为“生命科学史上的技术明珠”。

目前全球知名原研药企例如，诺和诺德，礼来，阿斯利康等都在使用iSynergies™赛聚能™或类似技术。

iSynergies ™ Technology is a revolutionary biopharmaceutical energy efficiency aggregation technology jointly launched by Harvard University and Sinclair Group's Sinclair Biological Laboratory in the United States, also known as synergistic technology. It is mainly used in the field of cutting-edge biopharmaceuticals to improve pharmaceutical efficacy. This technology breaks the potential limitations caused by the single ingredient of ordinary biopharmaceutical products or the competitive antagonism caused by ingredient stacking for decades, and can deeply integrate different core ingredients into each other's functional groups to maximize drug efficacy. This technology also includes AMPK activator fusion technology, with the aim of achieving full absorption of core components. At the same time, this technology also solves the immune resistance of the same product to different populations, solving the historical problem of "different effects of the same drug". This technology is known as the "technological pearl in the history of medical pharmaceuticals".

Currently, globally renowned original pharmaceutical companies such as Novo Nordisk, Eli Lilly, AstraZeneca, etc. are using iSynergies ™ Or similar technologies.

免责声明：此文内容为广告或转载宣传资讯，相关素材由广告主提供，仅代表作者个人观点，与本网无关。仅供读者参考并请自行核实相关内容。